Ceryvyn TherapeuticsASX:CYV -7.69% Cash Ratio is 0.19 as of Jun. 2025, which is 96% below its 10-year median of 4.45. The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 90.98% on this metric.
Ceryvyn Therapeutics has a Cash Ratio of 0.19. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Ceryvyn Therapeutics's Cash Ratio or its related term are showing as below:
ASX:CYV'
s Cash Ratio Range Over the Past 10 Years
Min: 0.19 Med: 4.45 Max: 38.05
Current: 0.19
During the past 13 years, Ceryvyn Therapeutics's highest Cash Ratio was 38.05. The lowest was 0.19. And the median was 4.45.
ASX:CYV's Cash Ratio is ranked worse than 90.98% of 1386
companies
in the Biotechnology industry
Industry Median: 2.94
vs ASX:CYV: 0.19
Ceryvyn Therapeutics (ASX:CYV) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Ceryvyn Therapeutics Cash Ratio Related Terms
Ceryvyn Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Ceryvyn Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYV vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (ASX:CYV) has a Cash Ratio of 0.19 as of Jun. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ceryvyn Therapeutics and its competitors. This is 96% below median its historical median of 4.45. Over the past decade, Ceryvyn Therapeutics' Cash Ratio has ranged from 0.19 to 38.05. According to the industry distribution chart, Ceryvyn Therapeutics ranks #1261 out of 1386 companies in the Biotechnology industry, placing it in the top 91%.
Is Ceryvyn Therapeutics' Cash Ratio too high?
Ceryvyn Therapeutics' current Cash Ratio of 0.19 is 96% below median its 10-year median of 4.45. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 38.05. The Biotechnology industry median Cash Ratio is 2.94. Ceryvyn Therapeutics' value of 0.19 is 93.5% below this industry median. Based on the distribution chart, Ceryvyn Therapeutics ranks #1261 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #1261 out of 1386 companies for Cash Ratio. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median Cash Ratio is 2.94. Ceryvyn Therapeutics' value of 0.19 is 93.5% below this benchmark. Historically, Ceryvyn Therapeutics' own Cash Ratio has ranged from 0.19 to 38.05 over the past decade. While the company's 10-year median is 4.45 vs. the industry median of 2.94, Ceryvyn Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ceryvyn Therapeutics's current Cash Ratio of 0.19 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current Cash Ratio is 0.19, which is 96% below median its own 10-year median of 4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Cash Ratio of 0.19. The current Cash Ratio is 0.19, which is 96% below median its 10-year median of 4.45 and 93.5% below the Biotechnology industry median of 2.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Cash Ratio is 0.19 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYV has been successfully added to your 